ENZC DD

ENZC Starter Pack

OTC Pink Current

Authorized Shares (A/S): 3 Billion

Outstanding Shares (O/S): 2.797 Billion

Insider Owned Shares: 512 Million (22.4% of the O/S)

Possible Dilution: most convertible debt has been exchanged for equity instruments that have a two-year conversion clause to postpone conversions for two years.

(Series C Preferred Shares)

*Source: 2020 Year End Update

Filings & Disclosure:

https://www.otcmarkets.com/stock/ENZC/disclosure

Highlights:

Monoclonal Antibodies (mAbs)

Clone 3 is non-toxic and has shown in initial in vitro testing to be effective against more than 95% of all strains and viral subtypes of HIV-1 against which it has been tested
Seven additional conserved target sites (some with 98% conserved sequences) have now been identified, with the assistance of AI, against which fully human anti-HIV monoclonal antibodies will be produced in its lab. This allows the administration of a "cocktail" of antibodies, all targeting conserved and expectedly immutable sites
Ongoing AI screening of 275,000 CoronaVirus isolates
Patented proprietary methodology for producing fully human monoclonal antibodies

(currently HIV & SARS CoV-2 & expect more to come in the future)

IPF / ITV (Immunotherapy Treatment)

Inactivated Pepsin Fraction (IPF) is the active drug substance of ITV-1 and is a purified extract of porcine pepsin
IPF/ITV has been successfully clinically tested and is pending the results of the ongoing toxicology study
Free from major neurological, gastrointestinal and hematological side effects seen in the antiretrovirals in use today

Potential Profits mAbs (From HIV only):

$105 Billion in the first 11 years

*Source: http://www.bioclonetics.com/profit-potential.html

*Bioclonetics merged into Enzolytics Q4 2020

Potential Profits (For IPF/ITV *HIV only*)

$10 Million

*For Harry Zhabilov Patent US7479538

*Source: https://enzolytics.com/patent

Upcoming News & Catalysts:

Government Funding
Completion of SARS-CoV-2 mAbs

Patent approval of provisional patent for Multiple Sclerosis ( Ser. No. 62/123341 )

Harry Zhabilov Patents US8309072 & US8066982

Including claims for the treatment of:

Hepatitis
Herpes
Rheumatoid Arthritis
Autoimmune Diabetes
Anti-Tumor (In-Vivo)
Anti-Cancer (In-Vivo)

Specific Cancers Mentioned:

Kidney Cancer
Melanoma
Pancreatic Cancer
Non-Hodgkin's Lymphoma
Lung Carcinoma
Prostate Cancer
Spinal Cell Carcinoma
Soft Tissue Sarcoma or Fibrosarcoma

To qualify to uplist to for OTCQB and eventually NASDAQ (PCAOB Audits In Process)

Toxicity Results on ITV-1 from BTS Research

Results from antibody studies at University of Strasbourg, France under direction of Dr. Christiane Moog, Ph.D, Research Director at INSERM
Macaque trials @ CA National Primate Research Center (UC Davis)
Updates RE: Antibody testing at San Raffaele Scientific Institute - Milan, Italy under direction of Dr. Gabriella Scarlatti, M.C., Ph.D., Head of Viral Evolution and Transmission Unit at SRSI
Info RE: FDA recognition of studies in Bulgaria & steps to gain FDA approval thru reciprocity with EMA (European Medicines Agency) for IPF / ITV
New Website

Misc Info:

Artificial Intelligence (AI) is being used to scan the hundreds of thousands of isolates that exist in 14 other prevalent viruses, ranging from influenza to Rabies to Ebola.
It is expected that each of these viruses will eventually have their own monoclonal antibody lines